Scott Juda - 01 Dec 2025 Form 4 Insider Report for Inmune Bio, Inc. (INMB)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
02 Dec 2025, 16:40:56 UTC
Prior SEC filing
18 Nov 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Scott Juda

Key filing fact

Scott Juda filed Form 4 for Inmune Bio, Inc. (INMB) on 02 Dec 2025.

Key facts

  • This page summarizes Scott Juda's Form 4 filing for Inmune Bio, Inc. (INMB).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 02 Dec 2025, 16:40.

Change

  • Previous filing in this sequence was filed on 18 Nov 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001767084 Primary reporting owner

Juda Scott

Relationship
Director
Address
C/O INMUNE BIO INC., 225 NE MIZNER BLVD., SUITE 640, BOCA RATON
Signature
/s/ Scott Juda
Signature date
02 Dec 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INMB transaction Derivative

Option (right to buy)

Award

Transaction value
$0
Shares
+150,000
Change %
Price
$0.000000
Shares after
150,000
Date
01 Dec 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
150,000
Exercise price
$1.48
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Granted pursuant to the Issuer's Second Amended and Restated 2021 Stock Incentive Plan. The option will become vested and exercisable pro rata on a monthly basis over three (3) years (1/36 per month) until the option is 100% vested, which shall occur on the three-year anniversary of the date of grant.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .